文献速递造血干细胞移植与细胞治疗

CRISPR靶向插入MAGT1恢复XMEN患者造血干细胞与淋巴细胞功能

CRISPR-targeted MAGT1 insertion restores XMEN patient hematopoietic stem cells and lymphocytes.
PubMed 文献 · Blood · 2021-01-01

本研究针对X连锁MAGT1缺陷伴EB病毒易感和N-连接糖基化缺陷(XMEN)疾病,开发基于CRISPR/Cas9与AAV的体外靶向基因治疗,将治疗性MAGT1基因插入其天然启动子调控的组成性位点。通过短暂增强同源定向修复并抑制AAV相关DNA损伤应答,在移植小鼠的XMEN造血干/祖细胞中实现超过60%的遗传校正,并恢复NK与CD8+ T细胞的NKG2D表达和功能。

要点

  • 优化CRISPR/Cas9 AAV条件可在移植小鼠XMEN HSPCs中实现>60%遗传校正。
  • 校正后恢复人NK与CD8+ T细胞的NKG2D表达和功能。
  • 该策略为XMEN提供两种潜在治疗选择并具备临床转化前景。

核心结论

  • 优化的CRISPR/Cas9 AAV靶向基因编辑可高效校正XMEN造血干/祖细胞并恢复淋巴细胞功能。

研究设计与样本

  • 利用CRISPR/Cas9腺相关病毒载体将治疗性MAGT1基因插入组成性位点,由内源启动子调控。

主要发现

  • 在移植小鼠的XMEN造血干/祖细胞中实现超过60%的遗传校正。
  • 恢复人NK细胞和CD8+ T细胞的NKG2D表达与功能。
  • 校正后的HSPCs可用于长期基因治疗。

临床怎么用

  • 该体外靶向基因治疗策略有望替代高死亡率的造血干细胞移植用于XMEN患者。

局限性

  • CRISPR/Cas9 AAV靶向基因编辑的临床转化受限于可植入的基因编辑HSPCs数量低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

XMEN disease, defined as "X-linked MAGT1 deficiency with increased susceptibility to Epstein-Barr virus infection and N-linked glycosylation defect," is a recently described primary immunodeficiency marked by defective T cells and natural killer (NK) cells. Unfortunately, a potentially curative hematopoietic stem cell transplantation is associated with high mortality rates. We sought to develop an ex vivo targeted gene therapy approach for patients with XMEN using a CRISPR/Cas9 adeno-associated vector (AAV) to insert a therapeutic MAGT1 gene at the constitutive locus under the regulation of the endogenous promoter. Clinical translation of CRISPR/Cas9 AAV-targeted gene editing (GE) is hampered by low engraftable gene-edited hematopoietic stem and progenitor cells (HSPCs). Here, we optimized GE conditions by transient enhancement of homology-directed repair while suppressing AAV-associated DNA damage response to achieve highly efficient (>60%) genetic correction in engrafting XMEN HSPCs in transplanted mice. Restored MAGT1 glycosylation function in human NK and CD8+ T cells restored NK group 2 member D (NKG2D) expression and function in XMEN lymphocytes for potential treatment of infections, and it corrected HSPCs for long-term gene therapy, thus offering 2 efficient therapeutic options for XMEN poised for clinical translation.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Brault J, Liu T, Bello E, et al. CRISPR-targeted MAGT1 insertion restores XMEN patient hematopoietic stem cells and lymphocytes. Blood. 2021. PMID: 34086870. doi:10.1182/blood.2021011192

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。